Nordic Pharma intros authorized generic of MaxitrolGeneric Maxitrol is used to treat and relieve bacterial eye infections. Samsung Bioepis releases Q2 2025 Biosimilar Market reportThe first wave of Stelara (ustekinumab) biosimilars show steep Wholesale Acquisition Cost discounts greater than 80%, the report finds. Camber touts 13 generic launches in Q1 2025 Camber anticipates receiving 54 new ANDA approvals and filing 35 more applications in 2025. Hikma acquires Novugen’s FDA-approved ANDA for generic Mekinist Trametinib is an orally administered kinase inhibitor medication used to treat certain cancers. Glenmark to launch generic Adderall Generic Adderall is used to treat attention deficit hyperactivity disorder and narcolepsy. U.S. Federal Court blocks Lupin, Zydus Life from bringing generic Myrbetriq to market Astellas Pharma's Myrbetriq is used to treat overactive bladder and neurogenic detrusor overactivity. Morris & Dickson partners with Mark Cuban Cost Plus Drugs The partnership aims to mitigate drug shortages, democratize access, enhance flexibility and streamline procurement. AAM comments on Section 232 investigation on pharmaceuticals AAM said tariffs will exacerbate drug shortages that hinder patient access today. FDA grants interchangeable designation for Celltrion’s Yuflyma Yuflyma is a high-concentration and citrate-free formulation of Humira biosimilar, approved for multiple inflammatory indications. Biocon Biologics secures market entry date for Eylea biosimilar Yesafili, a vascular endothelial growth factor inhibitor, is used to treat several different types of ophthalmology conditions and is a biosimilar of its Eylea. 1 2 3 4 5 Next Last
